title: Calcium-activated potassium channel KCa3.1 in lung dendritic cell migration.
abstract: Migration to draining lymph nodes is a critical requirement for dendritic cells (DCs) to control T-cell-mediated immunity. The calcium-activated potassium channel KCa3.1 has been shown to be involved in regulating cell migration in multiple cell types. In this study, KCa3.1 expression and its functional role in lung DC migration were examined. Fluorescence-labeled antigen was intranasally delivered into mouse lungs to label lung Ag-carrying DCs. Lung CD11c(high)CD11b(low) and CD11c(low)CD11b(high) DCs from PBS-treated and ovalbumin (OVA)-sensitized mice were sorted using MACS and FACS. Indo-1 and DiBAC4(3) were used to measure intracellular Ca(2+) and membrane potential, respectively. The mRNA expression of KCa3.1 was examined using real-time PCR. Expression of KCa3.1 protein and CCR7 was measured using flow cytometry. Migration of two lung DC subsets to lymphatic chemokines was examined using TransWell in the absence or presence of the KCa3.1 blocker TRAM-34. OVA sensitization up-regulated mRNA and protein expression of KCa3.1 in lung DCs, with a greater response by the CD11c(high)CD11b(low) than CD11c(low)CD11b(high) DCs. Although KCa3.1 expression in Ag-carrying DCs was higher than that in non-Ag-carrying DCs in OVA-sensitized mice, the difference was not as prominent. However, Ag-carrying lung DCs expressed significantly higher CCR7 than non-Ag-carrying DCs. CCL19, CCL21, and KCa3.1 activator 1-EBIO induced an increase in intracellular calcium in both DC subsets. In addition, 1-EBIO-induced calcium increase was suppressed by TRAM-34. In vitro blockade of KCa3.1 with TRAM-34 impaired CCL19/CCL21-induced transmigration. In conclusion, KCa3.1 expression in lung DCs is up-regulated by OVA sensitization in both lung DC subsets, and KCa3.1 is involved in lung DC migration to lymphatic chemokines.
authors.affiliation: Center for Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE 68178, USA.
authors.forename: Zhifei
authors.initials: Z
authors.lastname: Shao
authors.forename: Toluwalope O
authors.initials: TO
authors.lastname: Makinde
authors.forename: Devendra K
authors.initials: DK
authors.lastname: Agrawal
mesh_terms: D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D018845:CD11 Antigens / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D018925:Chemokines / Q000276:immunology; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels / Q000819:agonists / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology*; D008168:Lung / Q000187:drug effects / Q000276:immunology*; D008564:Membrane Potentials / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000276:immunology; D011720:Pyrazoles / Q000494:pharmacology; D054400:Receptors, CCR7 / Q000276:immunology
chemical_list: D001562:Benzimidazoles; D018845:CD11 Antigens; C515371:Ccr7 protein, mouse; D018925:Chemokines; D051660:Intermediate-Conductance Calcium-Activated Potassium Channels; C496925:Kcnn4 protein, mouse; D011720:Pyrazoles; D054400:Receptors, CCR7; C411671:TRAM 34; D010047:Ovalbumin; C102635:1-ethyl-2-benzimidazolinone; D002118:Calcium